Literature DB >> 26660518

The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent.

Vy Phan-Lai1, Yushe Dang1, Ekram Gad1, Jennifer Childs1, Mary L Disis2.   

Abstract

PURPOSE: Infusion of HER2-specific T cells, derived from vaccine-primed patients and expanded with IL2/IL12, has induced tumor regression in a minority of patients with metastatic treatment-refractory HER2(+) breast cancer. We questioned whether alteration of cytokine growth factors used to culture vaccine-primed T cells could improve antitumor activity. EXPERIMENTAL
DESIGN: Using the TgMMTV-neu murine mammary tumor model, we cultured T cells derived from mice immunized with a previously defined neu class II peptide, p98-114 (neu p98), and evaluated different cytokine combinations for expansion.
RESULTS: Infusion of neu p98-specific T-cell lines derived from all cytokine conditions evaluated resulted in significant antitumor activity compared with infused naïve splenocytes (P < 0.05). T cells cultured with IL2/IL21 could uniquely mediate complete regression of spontaneous mammary tumors. IL2/IL21 cultured neu-specific T cells demonstrated a different cytokine secretion pattern as compared with other cultured T cells; secreting high levels of TNFα and IL17 (P < 0.05). Moreover, tumor-infiltrating CD8(+) cells were significantly increased after the infusion of IL2/IL21 cultured T cells as compared with tumors treated with T cells expanded under other cytokine conditions (P < 0.001). The antitumor effect of the infusion of IL2/IL21 cultured cells was mediated by CD8 T cells. Depletion of TNFα or IL17, but not IFNγ, abrogated the tumor growth inhibition induced by the IL2/IL21 T cells and markedly decreased the influx of CD8 into tumors. Finally, IL2/IL21-cultured human antigen specific T cells also displayed a similar polyfunctional Th1/Th17 phenotype.
CONCLUSIONS: Expansion of HER2 vaccine-primed T cells with IL2/IL21 may have the potential to effectively mediate tumor regression when used in adoptive transfer. Clin Cancer Res; 22(9); 2207-16. ©2015 AACR. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26660518      PMCID: PMC4854769          DOI: 10.1158/1078-0432.CCR-15-2273

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  46 in total

1.  Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon.

Authors:  Agnes Le Bon; Nathalie Etchart; Cornelia Rossmann; Miranda Ashton; Sam Hou; Dirk Gewert; Persephone Borrow; David F Tough
Journal:  Nat Immunol       Date:  2003-09-21       Impact factor: 25.606

Review 2.  Cooperation between CD4+ and CD8+ T cells: when, where, and how.

Authors:  Flora Castellino; Ronald N Germain
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

3.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

Authors:  Eiichi Sato; Sara H Olson; Jiyoung Ahn; Brian Bundy; Hiroyoshi Nishikawa; Feng Qian; Achim A Jungbluth; Denise Frosina; Sacha Gnjatic; Christine Ambrosone; James Kepner; Tosin Odunsi; Gerd Ritter; Shashikant Lele; Yao-Tseng Chen; Haruo Ohtani; Lloyd J Old; Kunle Odunsi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

4.  IL-4 enhances long-term survival of CD28-deficient T cells.

Authors:  R M Stack; C B Thompson; F W Fitch
Journal:  J Immunol       Date:  1998-03-01       Impact factor: 5.422

5.  Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.

Authors:  S Y Shu; T Chou; K Sakai
Journal:  J Immunol       Date:  1989-07-15       Impact factor: 5.422

6.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Richard M Sherry; Suzanne L Topalian; Nicholas P Restifo; Richard E Royal; Udai Kammula; Don E White; Sharon A Mavroukakis; Linda J Rogers; Gerald J Gracia; Stephanie A Jones; David P Mangiameli; Michelle M Pelletier; Juan Gea-Banacloche; Michael R Robinson; David M Berman; Armando C Filie; Andrea Abati; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

7.  Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients.

Authors:  K L Knutson; K Schiffman; M L Disis
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

8.  IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion.

Authors:  K L Knutson; M L Disis
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

9.  Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice.

Authors:  Keith L Knutson; Bond Almand; Yushe Dang; Mary L Disis
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

Review 10.  Donor-derived CD19 chimeric antigen receptor T cells.

Authors:  Nathan Singh; David M Barrett
Journal:  Curr Opin Hematol       Date:  2015-11       Impact factor: 3.284

View more
  7 in total

1.  Toxoplasma: Immunity and Pathogenesis.

Authors:  Imtiaz A Khan; Charlotte Ouellette; Keer Chen; Magali Moretto
Journal:  Curr Clin Microbiol Rep       Date:  2019-02-04

2.  Impact of intra-tumoral IL17A and IL32 gene expression on T-cell responses and lymph node status in breast cancer patients.

Authors:  Shreyas Bhat; Nilesh Gardi; Sujata Hake; Nirupama Kotian; Sharada Sawant; Sadhana Kannan; Vani Parmar; Sangeeta Desai; Amit Dutt; Narendra N Joshi
Journal:  J Cancer Res Clin Oncol       Date:  2017-05-03       Impact factor: 4.553

3.  Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity.

Authors:  Mary K McKenna; Alexander Englisch; Benjamin Brenner; Tyler Smith; Valentina Hoyos; Masataka Suzuki; Malcolm K Brenner
Journal:  Mol Ther       Date:  2021-02-09       Impact factor: 11.454

Review 4.  Toxoplasma gondii: CD8 T Cells Cry for CD4 Help.

Authors:  Imtiaz A Khan; SuJin Hwang; Magali Moretto
Journal:  Front Cell Infect Microbiol       Date:  2019-05-01       Impact factor: 5.293

Review 5.  Recent advances in the role of Th17/Treg cells in tumor immunity and tumor therapy.

Authors:  Yin Qianmei; Su Zehong; Wang Guang; Li Hui; Gaojian Lian
Journal:  Immunol Res       Date:  2021-07-24       Impact factor: 2.829

6.  Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy.

Authors:  Julie Niogret; Hélène Berger; Cédric Rebe; Frederique Vegran; Francois Ghiringhelli; Fanny Chalmin; Romain Mary; Elise Ballot; Caroline Truntzer; Marion Thibaudin; Valentin Derangère; Christophe Hibos; Léa Hampe; David Rageot; Théo Accogli; Philippe Joubert; Bertrand Routy; James Harker
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

Review 7.  Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer.

Authors:  Margaux Saillard; Mara Cenerenti; Pedro Romero; Camilla Jandus
Journal:  Vaccines (Basel)       Date:  2021-05-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.